Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Apo-Doxy (00740713), Novo-Doxylin (00725250). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Doxycycline
All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules
Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
DIN 02512645: Apo-Doxycycline MR
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081224027; group id 31; item number 0065; lccId None; manufacturer id APX
Source form: MR Cap; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $3.1871; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02512645
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100192Interchangeable products
Apprilon · DIN 02375885 · not recorded
Shortage status: shortage reported ended July 3, 2026 (report last updated July 3, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02512645
Shortage record checked October 6, 2026
Apprilon · DIN 02375885 · 40 mg · MR capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Savings card: innoviCares lists Apprilon (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Apprilon · DIN 02375885
Manufacturer: Galderma Canada Inc; listing date 2021-07-30
Health Canada: Marketed since 2012-11-29 · brand APPRILON · ATC J01AA02 DOXYCYCLINE · form Capsule (immediate- and delayed-release) · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE MONOHYDRATE) 40 MG · company Galderma canada inc. · schedule Prescription
DIN 02375885: Apprilon
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081224027; group id 31; item number 0065; lccId None; manufacturer id GAC
Source form: MR Cap; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375885
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86128Interchangeable products
Apo-Doxycycline MR · DIN 02512645 · not recorded
Shortage status: resolved shortage (ended March 19, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375885
Shortage record checked October 6, 2026
Other products in the same Health Canada class (J01AA): coverage varies; not interchangeable
Minocycline: general benefit, not a benefit
Tetracycline (Tetracyn): general benefit, not a benefit
Tigecycline (Tygacil): general benefit
Doxycycline hyclate
Form:
11 of 11 products shown
8 general benefit · 3 not a benefit
Apo-Doxy-Tabs · DIN 00874256 · 100 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Doxy-Tabs · DIN 00874256
Manufacturer: Apotex Inc.; listing date 2009-05-20
Health Canada: Marketed since 1990-12-31 · brand APO-DOXY-TABS · ATC J01AA02 DOXYCYCLINE · form Tablet · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 100 MG · company Apotex inc · schedule Prescription
Apo-Doxy-Tabs: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4560). What the ministry pays, not the patient.
Ministry pays: $0.4560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00874256: Apo-Doxy-Tabs
Raw flags: sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id APX
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.4560; ministry $0.4560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00874256
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10383Interchangeable products
Bio-Doxycycline · DIN 02561115 · $0.4560
Doxycycline Tablets · DIN 02351242 · $0.4560
Jamp Doxycycline Tablets · DIN 02554372 · $0.4560
M-Doxycycline · DIN 02543478 · $0.4560
NRA-Doxycycline · DIN 02558505 · $0.4560
PRZ-Doxycycline · DIN 02536250 · $0.4560
Teva-Doxycycline · DIN 02158574 · $0.4560
Vibra-Tabs · DIN 00578452 · not recorded
Shortage status: resolved shortage (ended September 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00874256
Shortage record checked October 6, 2026
Bio-Doxycycline · DIN 02561115 · 100 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Bio-Doxycycline · DIN 02561115
Manufacturer: Biomed Pharma; listing date 2026-09-29
Health Canada: Marketed since 2026-05-26 · brand BIO-DOXYCYCLINE · ATC J01AA02 DOXYCYCLINE · form Tablet · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 100 MG · company Biomed pharma · schedule Prescription
Bio-Doxycycline: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4560). What the ministry pays, not the patient.
Ministry pays: $0.4560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02561115: Bio-Doxycycline
Raw flags: sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id BMP
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.4560; ministry $0.4560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02561115
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106411Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560
Doxycycline Tablets · DIN 02351242 · $0.4560
Jamp Doxycycline Tablets · DIN 02554372 · $0.4560
M-Doxycycline · DIN 02543478 · $0.4560
NRA-Doxycycline · DIN 02558505 · $0.4560
PRZ-Doxycycline · DIN 02536250 · $0.4560
Teva-Doxycycline · DIN 02158574 · $0.4560
Vibra-Tabs · DIN 00578452 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02561115
Jamp Doxycycline Tablets: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4560). What the ministry pays, not the patient.
Ministry pays: $0.4560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02554372: Jamp Doxycycline Tablets
Raw flags: sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id JPC
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.4560; ministry $0.4560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02554372
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104323Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560
Bio-Doxycycline · DIN 02561115 · $0.4560
Doxycycline Tablets · DIN 02351242 · $0.4560
M-Doxycycline · DIN 02543478 · $0.4560
NRA-Doxycycline · DIN 02558505 · $0.4560
PRZ-Doxycycline · DIN 02536250 · $0.4560
Teva-Doxycycline · DIN 02158574 · $0.4560
Vibra-Tabs · DIN 00578452 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554372
Shortage record checked October 6, 2026
M-Doxycycline · DIN 02543478 · 100 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
M-Doxycycline · DIN 02543478
Manufacturer: Mantra Pharma Inc.; listing date 2024-07-31
Health Canada: Marketed since 2024-06-05 · brand M-DOXYCYCLINE · ATC J01AA02 DOXYCYCLINE · form Tablet · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 100 MG · company Mantra pharma inc · schedule Prescription
M-Doxycycline: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4560). What the ministry pays, not the patient.
Ministry pays: $0.4560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02543478: M-Doxycycline
Raw flags: sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id MAT
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.4560; ministry $0.4560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02543478
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103193Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560
Bio-Doxycycline · DIN 02561115 · $0.4560
Doxycycline Tablets · DIN 02351242 · $0.4560
Jamp Doxycycline Tablets · DIN 02554372 · $0.4560
NRA-Doxycycline · DIN 02558505 · $0.4560
PRZ-Doxycycline · DIN 02536250 · $0.4560
Teva-Doxycycline · DIN 02158574 · $0.4560
Vibra-Tabs · DIN 00578452 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02543478
Shortage record checked October 6, 2026
NRA-Doxycycline · DIN 02558505 · 100 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
NRA-Doxycycline · DIN 02558505
Manufacturer: Nora Pharma; listing date 2026-03-31
Health Canada: Marketed since 2025-12-12 · brand NRA-DOXYCYCLINE · ATC J01AA02 DOXYCYCLINE · form Tablet · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 100 MG · company Nora pharma inc · schedule Prescription
NRA-Doxycycline: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4560). What the ministry pays, not the patient.
Ministry pays: $0.4560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02558505: NRA-Doxycycline
Raw flags: sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id NRA
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.4560; ministry $0.4560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02558505
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106175Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560
Bio-Doxycycline · DIN 02561115 · $0.4560
Doxycycline Tablets · DIN 02351242 · $0.4560
Jamp Doxycycline Tablets · DIN 02554372 · $0.4560
M-Doxycycline · DIN 02543478 · $0.4560
PRZ-Doxycycline · DIN 02536250 · $0.4560
Teva-Doxycycline · DIN 02158574 · $0.4560
Vibra-Tabs · DIN 00578452 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02558505
Shortage record checked October 6, 2026
PRZ-Doxycycline · DIN 02536250 · 100 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PRZ-Doxycycline · DIN 02536250
Manufacturer: Pharmaris Canada Inc.; listing date 2023-12-29
Health Canada: Marketed since 2023-09-01 · brand PRZ-DOXYCYCLINE · ATC J01AA02 DOXYCYCLINE · form Tablet · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 100 MG · company Pharmaris canada inc · schedule Prescription
PRZ-Doxycycline: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4560). What the ministry pays, not the patient.
Ministry pays: $0.4560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02536250: PRZ-Doxycycline
Raw flags: sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id PRZ
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.4560; ministry $0.4560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536250
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102504Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560
Bio-Doxycycline · DIN 02561115 · $0.4560
Doxycycline Tablets · DIN 02351242 · $0.4560
Jamp Doxycycline Tablets · DIN 02554372 · $0.4560
M-Doxycycline · DIN 02543478 · $0.4560
NRA-Doxycycline · DIN 02558505 · $0.4560
Teva-Doxycycline · DIN 02158574 · $0.4560
Vibra-Tabs · DIN 00578452 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536250
Shortage record checked October 6, 2026
Teva-Doxycycline · DIN 02158574 · 100 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Doxycycline · DIN 02158574
Manufacturer: Teva Canada Limited; listing date 2010-12-14
Health Canada: Marketed since 2014-02-07 · brand TEVA-DOXYCYCLINE · ATC J01AA02 DOXYCYCLINE · form Tablet · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 100 MG · company Teva canada limited · schedule Prescription
Teva-Doxycycline: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4560). What the ministry pays, not the patient.
Ministry pays: $0.4560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02158574: Teva-Doxycycline
Raw flags: sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id TEV
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.4560; ministry $0.4560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02158574
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18421Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560
Bio-Doxycycline · DIN 02561115 · $0.4560
Doxycycline Tablets · DIN 02351242 · $0.4560
Jamp Doxycycline Tablets · DIN 02554372 · $0.4560
M-Doxycycline · DIN 02543478 · $0.4560
NRA-Doxycycline · DIN 02558505 · $0.4560
PRZ-Doxycycline · DIN 02536250 · $0.4560
Vibra-Tabs · DIN 00578452 · not recorded
Shortage status: resolved shortage (ended April 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02158574
Shortage record checked October 6, 2026
Jamp Doxycycline · DIN 02528568 · 20 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Doxycycline · DIN 02528568
Manufacturer: Jamp Pharma Corporation; listing date 2024-06-28
Health Canada: Marketed since 2024-05-03 · brand JAMP DOXYCYCLINE · ATC A01AB22 DOXYCYCLINE · form Capsule · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 20 MG · company Jamp pharma corporation · schedule Prescription
DIN 02528568: Jamp Doxycycline
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081224028; group id 32; item number 0066; lccId None; manufacturer id JPC
Source form: Cap; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.3538; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528568
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101777Interchangeable products
PMS-Doxycycline · DIN 02247104 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02528568
Shortage record checked October 6, 2026
PMS-Doxycycline · DIN 02247104 · 20 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Doxycycline · DIN 02247104
Manufacturer: Pharmascience Inc.; listing date 2024-06-28
Health Canada: Marketed since 2025-12-01 · brand PMS-DOXYCYCLINE · ATC A01AB22 DOXYCYCLINE · form Capsule · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 20 MG · company Pharmascience inc · schedule Prescription
PMS-Doxycycline: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02247104: PMS-Doxycycline
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081224028; group id 32; item number 0066; lccId None; manufacturer id PMS
Source form: Cap; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247104
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71343Interchangeable products
Jamp Doxycycline · DIN 02528568 · not recorded
Shortage status: resolved shortage (ended November 18, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247104
Shortage record checked October 6, 2026
Doxycycline Tablets · DIN 02351242 · 100 mg · tablet
Doxycycline Tablets: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4560). What the ministry pays, not the patient.
Ministry pays: $0.4560 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02351242: Doxycycline Tablets
Raw flags: sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id SAI
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.4560; ministry $0.4560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02351242
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83643Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560
Bio-Doxycycline · DIN 02561115 · $0.4560
Jamp Doxycycline Tablets · DIN 02554372 · $0.4560
M-Doxycycline · DIN 02543478 · $0.4560
NRA-Doxycycline · DIN 02558505 · $0.4560
PRZ-Doxycycline · DIN 02536250 · $0.4560
Teva-Doxycycline · DIN 02158574 · $0.4560
Vibra-Tabs · DIN 00578452 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02351242
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 23, 2026 — choose a marketed DIN from the same-category list.
Vibra-Tabs · DIN 00578452 · 100 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-04-04 — choose a marketed DIN from the same-category list.Discontinued April 4, 2014 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-04-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-04-04 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Vibra-Tabs · DIN 00578452
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2014-04-04 · brand VIBRA-TABS · ATC J01AA02 DOXYCYCLINE · form Tablet · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 100 MG · company Pfizer canada ulc · schedule Prescription
Vibra-Tabs: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00578452: Vibra-Tabs
Raw flags: notABenefit=Y, sec3=Y
Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id PFI
Source form: Tab; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00578452
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6795Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560
Bio-Doxycycline · DIN 02561115 · $0.4560
Doxycycline Tablets · DIN 02351242 · $0.4560
Jamp Doxycycline Tablets · DIN 02554372 · $0.4560
M-Doxycycline · DIN 02543478 · $0.4560
NRA-Doxycycline · DIN 02558505 · $0.4560
PRZ-Doxycycline · DIN 02536250 · $0.4560
Teva-Doxycycline · DIN 02158574 · $0.4560
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00578452
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 4, 2014 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (J01AA): coverage varies; not interchangeable
Minocycline: general benefit, not a benefit
Tetracycline (Tetracyn): general benefit, not a benefit
Tigecycline (Tygacil): general benefit
Other drugs in the same formulary class (08:12:24 Tetracyclines) and how they are covered
Matched class: 08:12:24 Tetracyclines
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: TIGECYCLINE
Some products covered without a code (check the product listing): MINOCYCLINE HCL, TETRACYCLINE
08:12:24 Tetracyclines
INDICATIONS AND CLINICAL USE
APPRILON® (doxycycline) modified-release capsule is indicated for the treatment of only
inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect
was demonstrated for generalized erythema (redness) of rosacea.
APPRILON® contains an antibacterial ingredient, doxycycline. Misuse or overuse of
APPRILON® could lead to the development of drug-resistant bacteria. To reduce the
development of drug-resistant bacteria and maintain the effectiveness of doxycycline,
APPRILON® should only be used for the authorized indication and clinical use.
Pediatrics (<18 years of age):
Safety and efficacy in children below the age of 18 years have not been established.
Geriatrics (≥ 65 years of age):
Clinical studies of APPRILON did not include sufficient numbers of subjects aged 65 and over
to determine whether they respond differently from younger subjects.
https://pdf.hres.ca/dpd_pm/00045712.PDF
PM date: May 31, 2018
Source product: APPRILON; DIN 02375885; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications
APO-DOXY / APO-DOXY-TABS (doxycycline hyclate) may be indicated for the treatment of:
• Pneumonia
Single and multilobe pneumonia and bronchopneumonia due to susceptible strains of Streptococcus
pneunomiae and other Streptococcus spp., Staphylococcus spp., H. influenzae and Klebsiella
pneumoniae.
• Other Respiratory Tract Infections
Pharyngitis, tonsillitis, sinusitis, otitis media, bronchitis caused by susceptible strains of β- hemolytic
Streptococcus, Staphylococcus spp., Streptococcus pneunomiae and H. influenzae.
• Genitourinary Tract Infections
Pyelonephritis, cystitis, urethritis caused by susceptible strains of Klebsiella spp., Enterobacter
aerogenes, E. coli, Enterococcus spp., Staphylococcus spp., Streptococcus spp. and gonococcal
urethritis caused by Neisseria gonorrhoeae.
In adult patients with urethritis, cervicitis and vaginitis with a positive test for Chlamydia
trachomatis and/or Ureaplasma urealyticum, clinical resolution and absence of detectable
organisms have only been observed at completion of ORAL therapy with doxycycline. Relapses or
reinfection can occur. In these cases, limited data suggest …
https://pdf.hres.ca/dpd_pm/00084988.PDF
PM date: 2026-06-05
Source product: APO-DOXY-TABS; DIN 00874256; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Apo-Doxycycline MR · DIN 02512645
Shortage status: shortage reported ended 2026-07-03 (report last updated 2026-07-03); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02512645
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Apo-Doxycycline MR, Apprilon, Jamp Doxycycline, PMS-Doxycycline, Vibra-Tabs: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.